DNA Content/Cell Cycle Analysis, Colon (Inactive as of 05/19/14 Refer to 0095155)
Ordering Recommendation
Quantitative Flow Cytometry
Sun, Tue
3-9 days
New York DOH Approval Status
Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
Colon tumor tissue. 
Specimen Preparation
Paraffin embed tissue block enriched with colon tumor. If no normal tissue is included in the block, supply a control tissue block to be processed in parallel. 
Storage/Transport Temperature
Unacceptable Conditions
No tumor tissue remaining on block. Specimens fixed in Bouin's solution (picric acid), mercuric chloride containing fixatives (e.g., B5, Zenker's solution), or ethanol-based fixatives containing ethylene glycol, acetic acid or zinc chloride. Decalcified specimens. 
Include H&E stained slide and surgical pathology report. 
Paraffin block: Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable 
Reference Interval
Report components include: DNA content, S-phase interpretation, and copy of histogram.
Interpretive Data
In 694 patients with stage B2 or C colorectal adenocarcinomas, 51 percent were diploid, 11 percent were tetraploid and 38 percent were aneuploid. Diploid tumors had a higher survival rate than non-diploid (tetraploid and aneuploid) tumors. Non-diploid tumors were associated with distal tumors, higher stage and lymph node metastasis. The proliferation index (the sum of the percent of cells in S-phase plus the percent of cells in G2M phase) was a strong prognostic factor. A proliferation index cutoff of 20 percent provided the best prognostic separation of patients. [Cancer, 2006, vol.68(4): 879-888; Journal of Cancer Research and Clinical Oncology, 2002, 128:12, 650-658; Cancer Epidemiology, 2002, 11:1322].

Compliance Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

A thin section of each tissue submitted is stained with H&E to verify the presence of tumor. The DNA content of each tumor is classified as diploid or aneuploid. The DNA index is the ratio of tumor G0-G1 cells to normal G0-G1 cells.

The tumor-specific S-phase is used when possible. An average histogram S-phase is used for diploid and aneuploid tumors where the tumor and host S-phases cannot be separated. An average histogram S-phase is also used when the percentage of aneuploid cells in the histogram is low (less than 25 percent). The S-phase interpretation is based on comparison to other colon tumors and is controlled for histogram type (diploid, aneuploid). The appropriate population is divided into thirds and compared to the sample S-phase for an interpretation of low, moderate, or high S-phase.
CPT Code(s)
Component Test Code*Component Chart NameLOINC
0095733DNA Content, Colon30911-2
0095880DNA Content, Colon, S-Phase Interp.
2008896DNA Index, Colon
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
  • Breast Cancer aneuploidy
  • DNA Ploidy and S-Phase (Paraffin Block)